Prof. Marcello Persico. SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI Cattedra di Medicina Interna

Similar documents
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

Influenza A Virus Inhibits Type I IFN Signaling via NF-kB- Dependent Induction of SOCS-3 Expression

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Thomson Reuters Biomarker Solutions: Hepatitis C Treatment Biomarkers and special considerations in patients with Asthma

Fat and Viral Liver Disease

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Head of College Scholars List Scheme. Summer Studentship. Report Form

T Cell Maturation,Activation and Differentiation

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

Innovazione farmacologica e farmacologia clinica

Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)

Actions of Hormones on Target Cells Page 1. Actions of Hormones on Target Cells Page 2. Goals/ What You Need to Know Goals What You Need to Know

Peak intensity Trypsin. Protein Sequence Before trypsin digestion After digestion with trypsin for 24 h digestion

SHAHID AZIZ DO, FACOI.

Understanding the immune response to bacterial infections

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?

Hepatitis C Glossary of Terms

岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹

No Disclosures. Learning Objectives 10/25/13

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)

Figure S1. SDS-PAGE of purified rtmd proteins Figure S2. rtmd1 interferes with chemotaxis of HUVECs induced by rtmd23

Supplementary Materials for

Describe how these hormones exert control quickly by changes in phosphorylation state of enzyme, and more slowly by changes of gene expression

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

OriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation

Notch 1 -dependent regulation of cell fate in colorectal cancer

Engineering of Yellow Mosaic Virus Resistance (YMVR) in Blackgram. Project ID: 1 April 2000 to 31 August Project Duration:

CD3/TCR stimulation and surface detection Determination of specificity of intracellular detection of IL-7Rα by flow cytometry

DNA Vaccine for Chronic Hepatitis C

SDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and

RNAi Shooting the Messenger!

HCV Treatment Failure

Approach to Patients with Elevated AFP without Liver Mass. Cesar Yaghi MD Hotel Dieu de France Université Saint Joseph

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

FGF-1 as Cosmetic Supplement

Hepatitis C treatment update

How To Understand The Effects Of A Drug On Your Health

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

Update on hepatitis C: treatment and care and future directions

HEPATITIS COINFECTIONS

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

New IDSA/AASLD Guidelines for Hepatitis C

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Fattori implicati nel rimodellamento tissutale epatico

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

B Cell Generation, Activation & Differentiation. B cell maturation

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

FARMACI PERSONALIZZATI PER

Diabetes and Drug Development

Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System

Physiology, Aberdeen AB24 2TZ *Corresponding authors:

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS

Meccanismi di resistenza all inibizione della via di segnale PI3K/Akt/mTOR nella LAM

Diabetes and Insulin Signaling

Surveillance for Hepatocellular Carcinoma

Micro RNAs: potentielle Biomarker für das. Blutspenderscreening

Supplemental Information. McBrayer et al. Supplemental Data

EVALUATION OF LIVER FIBROSIS BY FIBROSCAN

hydrocortisone (5 mg/ml), EGF (10 µg/ml) and Heparin (5000 U/ml). Antibodies against the N-terminal peptide of MEK1 (MEK1-N) and against Flotillin 1

Normal values of IGF1 and IGFBP3. Kučera R., Vrzalová J., Fuchsová R., Topolčan O., Tichopád A.

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

How to construct transgenic mice

REAL TIME PCR SYBR GREEN

Give a NOD to diabetes:

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, , pp.

Coinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes

Genolution Pharmaceuticals, Inc. Life Science and Molecular Diagnostic Products

MOL.911 HNL Expression

CHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA

HBV DNA < monitoring interferon Rx

Chapter 18: Applications of Immunology

Post AASLD Update in HCV Torino, 10 Gennaio Fattori che possono influenzare il trattamento: RVR e Lead in

Autoimmunity and immunemediated. FOCiS. Lecture outline

Cirrhosis and HCV. Jonathan Israel M.D.

Clinical Criteria for Hepatitis C (HCV) Therapy

Verso un interruzione dei farmaci nella leucemia mieloide cronica

Gene Therapy- Past, Present and Future. Mark A. Kay MD, PhD Dennis Farrey Family Professor Departments of Pediatrics and Genetics Stanford University

Medical publications on HBV and HCV Coinfection

MEDICAL POLICY STATEMENT

Diabetes and Obesity. The diabesity epidemic

Chapter-21b: Hormones and Receptors

Transcription:

9 11 Marzo 2011 III Sessione The New Era of Host-Related Genetic Markers in HCV disease and Treatment: SOCS SNP and response to antiviral treatment Prof. Marcello Persico SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI Cattedra di Medicina Interna

SOCS3 IFN-LAMBA3/IL 28

Patients achieving an SVR (%) A number of baseline factors have a strong impact on SVR PEGASYS plus COPEGUS ; * p<0.05 80 70 60 50 67* 52 64* 56 69* 51 70* 59* 63* 56 61* 48 76* 49 59 57 71* 55 40 30 34 20 10 0 Swain, M et al.

Insulin resistance decreases SVR in chronic hepatitis C ROMERO-GOMEZ et al, Gastroenterology 2005;128:636-641

HCV Core Protein induces IR, Liver Steatosis and Hepatocellular Carcinoma in Transgenic Mice at birth 16 mo 17 mo "nodule-in-nodule" Anti-TNF-a antibody restores insulin sensitivity MORIYA et al, Nature Med 1998 SHINTANI et al, Gastroenterology 2004

The HCV Core Protein Decreases IRS1 and IRS2 by Upregulating SOCS-3 KAWAGUCHI et al, Am J Path 2004;165:1499-1508

Molecular mechanisms of insulin resistance Free fatty acids Proteasomal degradation (SOCS, PPARg) TNFa Tyr-P IRS1 Ser-P Tyr-P IRS1 Ser-P IKK PI3K AcylCoA Diacylglycerol PKC JNK MAPK Insulin action

mtor activity (450 nm) Are insulin resistance mechanisms HCV genotype-specific? 1b 3a GFP Huh-7 1b 3a GFP Huh7 IRS-1 SOCS-7 IRS-2 -Actin -Actin 0.35 0.3 3a 3a + Ro GFP GFP + Ro Huh7 Huh7 + Ro 0.25 0.2 IRS-1 0.15 -Actin 0.1 0.05 0 0 1b 3a GFP Huh-7 PAZIENZA et al, Hepatology 2007

x core x SOCS3 x x x x x Gale Nature 2005

Il pathway JAK/STAT SHP PIAS SOCS Regolazione negativa Mx-A 2-5 OAS Effettori antivirali

IMMUNOISTOCHIMICA A: obeso non responder; B: responder ; C: controllo negativo L espressione epatica di Socs 3 è indotta da citochine e da ormoni associati all obesità ed all insulino resistenza. Una marcata riduzione di SOCS3 è stata notata in ratti obesi mancanti del TNF-α.

Model of IFN resistance in chronic HCV infection Huang et al. Gastro 2007 HCV infection leads to endogenous IFN production and also to increased expression of SOCS3, either directly by a viral protein or indirectly by an IFN inhibitory factor (IL-6 or other soluble factors). SOCS3 can suppress JAK-STAT signaling by blocking the IFN-induced formation of ISGF3. With exogenous IFN treatment, SOCS3 is induced, preventing further ISG activation and markedly blunting the IFN response

Analisi di espressione genica su pazienti con epatite cronica HCV-correlata A) 22 campioni: 11 SVR + 11 NR B) 22 campioni: 15 SVR + 7 NR Mann Whitney test; P<0.05 Persico et al, GUT, 2008

La variante allelica -4874 A è associata ad elevati livelli di espressione di SOCS3 QRT-PCR: 12 AA (1.1; 1.60 ± 0.31) 16 GG (0.40; 0.81 ± 0.20) Mann Whitney test; P<0.05 Western blotting, 10 HCV NR: 6 AA: (15.42; 15.34 ± 0.10) 4 GG: (14.34; 14.37 ± 0.35) Mann Whitney test; P<0.05 Persico et al, GUT, 2007

Hepatology 2007Oct;46(4):1009-15.

1 2 1: Andamento di Socs3 ai vari tempi e nei diversi genotipi, con particolare sulla seconda settimana a cui si osserva il picco di espressione. 2: Western blotting della proteina socs3 al tempo in cui si osserva il picco di espressione genica Persico et al. CCLM, 2009

HCV TNF-a SOCS-3 binding to IRS-1 causes its proteasomal degradation binding to Janus kinase inhibits Tyr-phosphorylation of STAT1 interference with the insulin signaling X interference with the IFN-asignaling

IFN-Lambdas induced STAT1 and STAT3 phosphorylation. A control HepG2 clone (pcr3.1/mock) and SOCS-1 (pcr3.1/socs-1) overexpressing clone were incubated with 1000 U/ml IFN-a, 100 ng/ml IL-28A, and 100 ng/ml IL-29 for 15 min, respectively. (A) Tyrosine phosphorylation of STAT1 (pstat1) in mock-transfected cells was diminished in SOCS-1 overexpressing cells. (B) Tyrosine phosphorylation of STAT3 (pstat3) after stimulation with IFN-a or IFN-lambdas. SOCS-1 overexpression completely abolished STAT3 phosphorylation. Shown is one representative Western blot out of four performed experiments. S. Brand et al. - Biochemical and Biophysical Research Communications 331 (2005) 543 548

IFN-lambdas induced 20,50-OAS gene expression which was inhibited by SOCS-1 over expression. A control HepG2 clone (pcr3.1/mock) and SOCS-1 (pcr3.1/socs-1) overexpressing clone were incubated with 1000 U/ml IFN-a, 10 ng/ml IL-28A or 10 ng/ml IL- 29 for 5 h, respectively. 20,50-OAS mrna expression was determined by Northern blot analysis (upper panel). Equal loading is confirmed by ethidium bromide staining of 28s and 18s rrna (middle panel). Baseline mrna level in the control pcr3.1/mock clone was set as 1.0. Baseline and stimulus induced 20,50- OAS mrna levels in all other groups were calculated as -fold increase in comparison to this control group (lower panel). Shown is one representative Northern blot out of three performed experiments. S. Brand et al. - Biochemical and Biophysical Research Communications 331 (2005) 543 548

IFN-lambdas induced MxA gene expression which was inhibited by SOCS-1 overexpression. A control HepG2 clone (pcr3.1/mock) and SOCS-1 (pcr3.1/socs-1) overexpressing clone were incubated with 1000 U/ml IFN-a, 10 ng/ml IL-28A or 10 ng/ml IL-29 for 5 h, respectively. MxA mrna expression was determined by Northern blot analysis (upper panel). Equal loading is confirmed by ethidium bromide staining of 28s and 18s rrna (middle panel). Baseline mrna level in the control pcr3.1/mock clone was set as 1.0. Baseline and stimulus induced MxA mrna levels in all other groups were calculated as -fold increase in comparison to this control group (lower panel). Shown is one representative Northern blot out of three performed experiments. S. Brand et al. / Biochemical and Biophysical Research Communications 331 (2005) 543 548

SOCS 3